This process involves transferring preformed peptide–MHC (p‐MHC) class I or II molecules from tumor cells to DCs, including both cDC1s and cDC2s, through the uptake of tumor‐derived extracellular vesicles or via horizontal transfer mechanisms such as trogocytosis at the plasma membrane [57, 58]. This evidence concerns the gene HLA-C and neoplasm.